---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-23-000097"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2023-06-06T23:59:59+00:00"
generated_at: "2026-06-14T06:27:04.411230+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kiora Pharmaceuticals closes $6.3M underwritten public offering, including full over-allotment

## Summary
- Gross proceeds of $6.3M from offering of common stock, Series F convertible preferred, and Class C/D warrants.
- Net proceeds to Kiora approximately $5.6M after underwriting discounts and offering expenses.
- Underwriter's over-allotment option fully exercised, adding 750,000 common shares and warrants.
- Series F preferred convertible into common; holder limited to 4.99% beneficial ownership (can increase to 9.99%).
- Class C warrants expire in 5 years, Class D in 1 year; both have initial exercise price of $1.10 per share.

## SEC filing metadata
- accession: 0001372514-23-000097
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2023-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000097/0001372514-23-000097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000097/kprx-20230602.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-23-000097
- JSON: https://secwatch.observer/filing/0001372514-23-000097.json
- Plain text: https://secwatch.observer/filing/0001372514-23-000097.txt

## Key facts
- Material Agreements
  KIORA PHARMACEUTICALS INC entered into Underwriting Agreement with Ladenburg Thalmann & Co. Inc. valued at Underwriting Agreement for public offering of common stock, preferred stock, and warrants, net proce (effective 2023-06-02).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Ladenburg Thalmann & Co. Inc.
  - Value: Underwriting Agreement for public offering of common stock, preferred stock, and warrants, net proce
  - Effective: 2023-06-02
  source text: On June 2, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Ladenburg Thalmann & Co. Inc., as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell, in a firm commitment underwritten public offering by the Company (the “Public Offering”), (i) 1,447,628 shares of common stock (the “Common Shares”), (ii) 3,908 shares of Series F Convertible Preferred Stock (the “Preferred Shares”) convertible into up to 3,552,372 shares of common stock, (iii) Class C Warrants (the “Class C Warrants”) to purchase up to 5,000,000 shares of common stock, and (iv) Class D Warrants (the “Class D Warrants” and, together with the Class C Warrants, the “Warrants”) to purchase up to 5,000,000 shares of common stock, priced at a public offering price of $1.10 per Common Share, Class C Warrant and Class D Warrant or $999.90 per Preferred Share, 909 Class C Warrants and 909 Class D Warrants.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000097/0001372514-23-000097-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.